Latest Little Green Pharma (ASX:LGP) News

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.

Little Green Pharma has pushed back the Federal Court hearing for its Cannatrek acquisition to late May, setting a new timetable that includes a shareholder vote on May 22 and implementation targeted for June 1.

Little Green Pharma has postponed the shareholder vote on issuing new shares tied to its Cannatrek acquisition, pushing the decision back a month to allow time to meet outstanding conditions. Other resolutions will proceed as planned on April 22.

Rare earths, lithium and antimony stocks drove the week, while a handful of capital raisings and profit warnings hit hard. The biggest gains came from drilling wins and deal news. The sharpest falls came where investors faced dilution, weaker earnings or takeover friction.

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.

Little Green Pharma Ltd (ASX:LGP) has secured overwhelming shareholder approval from Cannatrek Ltd for its proposed acquisition scheme, advancing the transaction toward Federal Court approval and implementation by early May 2026.

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.